



Karen L. Kelly, M.D.

Clinical Interests Dr. Kelly is an internationally recognized lung cancer expert dedicated to providing enhanced cancer care through cutting-edge clinical trials. Dr. Kelly's lung cancer research spans the spectrum of the disease from prevention to treatment. She has been at the forefront of clinical trials development evaluating drugs to treat lung cancer and novel compounds to prevent lung cancer. She is also involved in developing biomarkers for screening and early detection of lung cancer. Dr. Kelly has authored or co-authored more than 190 publications, including original papers, reviews and book chapters. She frequently lectures on lung cancer topics, nationally and internationally. Dr. Kelly is a long-standing active member of ASCO, SWOG and the IASLC.

Research/Academic Interests Dr. Kelly is an internationally recognized lung cancer expert dedicated to providing enhanced cancer care through cutting-edge clinical trials. Dr. Kelly's lung cancer research spans the spectrum of the disease from prevention to treatment. She has been at the forefront of clinical trials development evaluating drugs to treat lung cancer and novel compounds to prevent lung cancer. She is also involved in developing biomarkers for screening and early detection of lung cancer. Dr. Kelly has authored or co-authored more than 200 190 publications, including original papers, reviews and book chapters. She frequently lectures on lung cancer topics, nationally and internationally. Dr. Kelly is a long-standing active member of ASCO, SWOG and the IASLC.

Title Professor
Associate Director for Clinical Research, UC Davis Comprehensive Cancer Center
Jennifer Rene Harmon Tegley and Elizabeth Erica Harmon Endowed Chair in Cancer Clinical Research

Specialty Hematology/Oncology, [Cancer](#)

Department [Internal Medicine](#)

Division Hematology and Oncology

Center/Program Affiliation [UC Davis Comprehensive Cancer Center](#)

Address/Phone UC Davis Comprehensive Cancer Center, 2279 45th Street Sacramento, CA 95817
Phone: 916-734-5959

Additional Phone Clinic Fax: 916-703-5265
Clinic Referral Phone: 916-703-5210
Physician Referrals: 800-4-UCDAVIS (800-482-3284)



Karen L. Kelly, M.D.

Education	M.D., University of Kansas School of Medicine, Kansas City KS 1984 B.S., Emporia State University, Emporia KS 1978
Internships	Internal Medicine, University of Colorado Health Sciences Center, Denver CO 1984-1985
Residency	Internal Medicine, University of Colorado Health Sciences Center, Denver CO 1985-1987
Fellowships	Hematology/Oncology, University of Colorado Health Sciences Center, Denver CO 1987-1990
Board Certifications	American Board of Internal Medicine American Board of Internal Medicine, Medical Oncology
Professional Memberships	American Association for Cancer Research (AACR) American Society of Clinical Oncology (ASCO) European Society of Medical Oncology (ESMO) International Association for the Study of Lung Cancer (IASLC) National Lung Cancer Partnership (formerly Women Against Lung Cancer) Southwest Oncology Group (SWOG)
Honors and Awards	America's Top Doctors for Cancer, 2006, 2007, 2008, 2009, 2013, 2014, 2016, 2017, 2018, 2019 America's Top Doctors, 2006, 2007, 2008, 2010, 2011, 2012, 2013, 2014, 2015, 2016, 2017, 2018, 2019 Best Doctors in America, 2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012, 2013, 2014, 2015, 2016, 2017, 2018, 2019 Fellow, American Society of Clinical Oncology (FASCO), 2012, 2013, 2014, 2015, 2016, 2017, 2018, 2019 Sacramento Magazine Top Doctors, 2011, 2012, 2013, 2014, 2015, 2016, 2017 Bonnie J. Addario Lung Cancer Foundation A Breath Away from the Cure Award Recipient for excellence in oncology, early detection, coordinated treatment, care and compassion for those with lung cancer, 2017 Fellow, Hedwig van Ameringen Executive Leadership in Academic Medicine (ELAM) Program for Women, 2012, 2013 Kansas City Business Journal Best Doctors in Kansas City, 2010 Glasgow Memorial Achievement Citation for Scholastic Achievement, 1984 Alpha Omega Alpha Honor Medical Society, 1983
Select Recent Publications	For a comprehensive list of Dr. Kelly's publications, please click here (opens new window).



Karen L. Kelly, M.D.

Gould MK, Smith-Bindman R, Kelly K, Altman DE, Barjaktarevic I, Creekmur B, de Bie E, Dyer DS, Mortani Barbosa EJ Jr, Mularski RA, Qi L, Vaszar LT, Yu S, Miglioretti DL. Methods for the Watch the Spot Trial: A Pragmatic Trial of More vs. Less Intensive Strategies for Active Surveillance of Small Pulmonary Nodules. *Ann Am Thorac Soc*. 2019 Dec;16(12):1567-1576. doi:10.1513/AnnalsATS.201903-268SD.

Edelman MJ, Redman MW, Albain KS, McGary E, Rafique NM, Petro D, Waqar SN, Griffin K, Miao J, Papadimitrakopoulou VA, Kelly K, Gandara DR, Herbst R. Brief Report: SWOG S1400C (NCT02154490)-A phase II study of palbociclib for previously treated cell cycle gene alteration positive patients with stage IV squamous cell lung cancer (Lung-MAP sub-study). *J Thorac Oncol*. 2019 Oct;14(10):1853-1859. doi:10.1016/j.jtho.2019.06.027. Epub 2019 Jul 11.

Aggarwal C, Redman MW, Lara Jr PN, Borghaei H, Hoffman P, Bradley JD, Minichiello K, Miao J, Mack PC, Papadimitrakopoulou VA, Herbst R, Kelly K, Gandara DR. SWOG S1400D: Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 for Previously-treated Patients with Fibroblast Growth Factor Pathwayactivated Stage IV Squamous Cell Lung Cancer (lung-MAP Substudy). *J Thorac Oncol*. 2019 Oct;14(10):1847-1852. doi:10.1016/j.jtho.2019.05.041. Epub 2019 Jun 11.

Langer CJ, Redman MW, Wade JL III, Aggarwal C, Bradley JD, Crawford J, Stella PJ, Knapp MH, Miao Jieling, Minichiello K, Herbst R, Kelly K, Gandara DR, Papadimitrakopoulou V. Brief Report: SWOG S1400B (NCT02785913), A Phase II Study of GDC-0032 (Taselisib) for Previously Treated P13K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study). *J Thorac Oncol*. 2019 Oct;14(10):1839-1846. doi:10.1016/j.jtho.2019.05.029. Epub 2019 May 31.

Karim NA, Kelly K. Role of Targeted Therapy and Immune Checkpoint Blockers in Advanced Non-Small Cell Lung Cancer: A Review. *Oncologist*. 2019 Sep; 24(9): 1270–1284. Published online 2019 Mar 26. doi:10.1634/theoncologist.2018-0112.

Tsao A, Miao J, Wistuba II, Vogelzang NJ, Heymach JV, Fossella FV, Lu C, Velasco MR, Box-



Karen L. Kelly, M.D.

Noriega B, Hueftle JG, Gadgeel S, Redman MW, Gandara DR, Kelly K. Phase II Trial of Cediranib in combination with cisplatin and pemetrexed in chemo naive patients with unresectable malignant pleural mesothelioma (SWOG S0905). *J Thorac Oncol*. 2019 Aug 6;37(28):2537-2547. doi: 10.1200/JCO.19.00269.

Ganti AK, Wang X, Stinchcombe TE, Wang YA, Bradley JD, Cohen H, Kelly K, Paulus R, Ramalingam S, Vokes E, Pang H. Clinical Prognostic Model for Older Patients with Advanced Non-Small Cell Lung Cancer. *J Geriatr Oncol*. 2019 Jul;10(4):555-559. doi:10.1016/j.jgo.2019.02.007. Epub 2019 Feb 21.

Peguero J, Sohal D, O'Neil B, Safran H, Kelly K, Grilley-Olson JE, Subbiah V, Nadauld L, Purkayastha D, Ricart A, Kang BP, Eder JP. Tissue/Site-Agnostic Study of Ribociclib for Tumors that have Cyclin D-CDK4/6 Pathway Genomic Alterations: A Phase 2, Open-label, Single-arm Basket Study. *JCO Precis Oncol*. 2019;3:1-10. doi:10.1200/PO.18.00383.

David EA, Andersen SW, Beckett LA, Melnikow J, Clark JM, Brown LM, Cooke DT, Kelly K, Canter RJ. Survival benefits associated with surgery for advanced non-small cell lung cancer. *J Thorac Cardiovasc Surg*. 2019 Apr;157(4):1620-1628. doi:10.1016/j.jtcvs.2018.10.140. Epub 2018 Nov 14.

Schild SE, Fan W, Stinchcombe TE, Vokes EE, Ramalingam SS, Bradley JD, Kelly K, Pang HH, Wang X. Toxicity Related to Radiotherapy Dose and Targeting Strategy: A Pooled Analysis of Cooperative Group Trials of Combined Modality Therapy for Locally Advanced Non-Small Cell Lung Cancer. *J Thorac Oncol*. 2019 Feb;14(2):298-303. doi:10.1016/j.jtho.2018.09.021. Epub 2018 Oct 4.

© 2021 UC Regents